Diagnostic value of serum D‐dimer,<scp>CA</scp>125, and neutrophil‐to‐lymphocyte ratio in differentiating ovarian cancer and endometriosis

Chen, Lifeng; Wang, Xinyan; Shu, Jing; Xu, Sheng; Wu, Qing; Yu, Yan

doi:10.1002/ijgo.12949

Cited by 25 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When the cutoff value of the D-dimer was increased to 981 ng/mL, it was found the survival period of the above group was significantly lower than the below group, and the increase of the cut-off value of the D-dimer to 981 ng/mL may be an important clinical indicator to evaluate the prognosis of patients with advanced NSCLC. D-dimer, as the degradation product of fibrinolytic protein, reflects whether the body's internal fibrinolytic system is abnormal, and the high content of d-dimer in plasma is closely related to the poor prognosis of patients with advanced NSCLC (20), breast cancer (26), ovarian cancer (27), pancreatic cancer (28) and colon cancer (29). However, in this study, it was found that the original cut-off value of 500 ng/mL as D-dimer could not adequately assess the prognosis of advanced NSCLC patients and the enhance of its cut-off value was firmly related to the survival of advanced NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Chen¹,

Li²,

Li³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: Tumor-related coagulation dysfunction has been reported to be closely associated with poor prognosis. The present study is aimed to evaluate the prognostic prediction of an elevated plasma D-dimer cut-off value in advanced non-small cell lung cancer (NSCLC).Methods: A total of 233 patients initially diagnosed with advanced NSCLC were retrospectively analyzed, an elevated plasma cut-off value 981 ng/mL of D-dimer, which was instead of the clinical cut-off value 500 mg/mL, was used to determine the high and low. Univariate analysis using the Kaplan-Meier method and log-ranking test, and the multivariate analysis using the Cox proportional hazard regression model were performed.Results: Results showed when using the D-dimer value of 500 ng/mL as an evaluation standard, there was no significant difference in gender, age, smoking status, histopathology and overall survival rate between normal D-dimer (≤500 ng/mL) and high D-dimer (>500 ng/mL) group. However, when the evaluation standard for plasma D-dimer was set at 981 ng/mL, the age distribution of the high D-dimer (>981 ng/mL) group was significantly different from the normal D-dimer (≤981 ng/mL) group. Moreover, the overall survival rate in the high D-dimer (>981 ng/mL) group was significantly lower than that in the normal D-dimer (≤981 ng/mL) group. Conclusions:The present study implied that increasing the plasma D-dimer cut-off value to 981 ng/mL is more beneficial to prognosis prediction in advanced NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Chen¹,

Li²,

Li³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…Another study showed that the D-dimer level increased in 73% stage I ovarian cancer patients, whereas CA-125 increased in only 33%, so D-dimer is more sensitive in stage I ovarian cancer patients (46). Moreover, a previous study showed that D-dimer is a useful marker in differentiating ovarian cancer and endometriosis, with a sensitivity of 93.2% and a specificity of 87.5% (47). Therefore, the inclusion of D-Dimer was expected to improve the accuracy in identifying the subtypes of ovarian cancer.…”

Section: Further Optimizationmentioning

confidence: 97%

Diagnostic Accuracy of the ADNEX Model for Ovarian Cancer at the 15% Cut-Off Value: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

ObjectivesTo evaluate the diagnostic accuracy of the ADNEX model for ovarian cancer at the 15% cut-off value.MethodsStudies on the identified diagnosis of the ADNEX model for ovarian cancer published in PubMed, Embase, the Cochrane Library and Web of Science databases from January 1st, 2014 to February 20th, 2021 were searched. Two researchers independently screened the retrieved studies and extracted the basic features and parameter data. The quality of the eligible studies was evaluated by Quality Assessment of Diagnostic Accuracy Studies-2, and the result was summarized by Review Manager 5.3. Meta-Disc 1.4 and STATA 16.0 were used in statistical analysis. Heterogeneity of this meta-analysis was calculated. Meta-regression was performed to investigate the potential sources of heterogeneity. Sensitivity analysis and Deek’s funnel plot analysis were conducted to evaluate the stability and publication bias, respectively.Results280 studies were initially retrieved through the search strategy, and 10 eligible studies were ultimately included. The random-effects model was selected for data synthesis. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and the area under the summary receiver operating characteristic curve were 0.92 (95% CI: 0.89–0.94), 0.82 (95% CI: 0.78–0.86), 5.2 (95% CI: 4.1–6.4), 0.10 (95% CI: 0.07–0.13), 54.0 (95% CI: 37.0–77.0) and 0.95 (95% CI: 0.91–0.95). Meta-regression based on study design, country, enrollment and blind method was not statistically significant. This meta-analysis was stable with no obvious publication bias.ConclusionsThe ADNEX model at the 15% cut-off had high diagnostic accuracy in identifying ovarian cancer.

show abstract

“…Moreover, the quantification of white blood cells (WBCs), lymphocytes, monocytes, neutrophils and platelets from full blood counts were found to be closely correlated with disease status and outcome. In addition, several combinatorial parameters, such as lymphocyte-to-monocyte ratio (LMR), fibrinogen-to-albumin ratio (FAR), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) have been identified as prognostic biomarkers in several malignancies, including ovarian cancer [14][15][16]. If these parameters could be integrated into a model to formulate a tool to predict malignancy in ovarian masses, it would be useful to improve the therapeutic plans and surgical options for patients with ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses

Guo

Jiang

Ouyang

et al. 2021

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

Diagnostic value of serum D‐dimer,CA125, and neutrophil‐to‐lymphocyte ratio in differentiating ovarian cancer and endometriosis

Cited by 25 publications

References 26 publications

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Diagnostic Accuracy of the ADNEX Model for Ovarian Cancer at the 15% Cut-Off Value: A Systematic Review and Meta-Analysis

A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses

Contact Info

Product

Resources

About